A5047010496- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease and Transplantation
- Cancer Mechanisms and Therapy
- Advanced Radiotherapy Techniques
- Radiation Therapy and Dosimetry
- Liver physiology and pathology
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Statistical Methods in Clinical Trials
University of Duisburg-Essen
2022-2025
Essen University Hospital
2022-2024
Deutschen Konsortium für Translationale Krebsforschung
2023
Evaluation of the efficacy and safety atezolizumab/bevacizumab in a real-world HCC cohort, including patients with impaired liver function prior systemic therapy.
Objective: To evaluate the prognostic value of pre-therapeutic inflammatory markers before transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in treatment hepatocellular carcinoma (HCC). Methods: A total 155 patients (81% male, median age: 68 years) who underwent first-time DSM-TACE between 07/13 and 06/22 were included study. Inflammatory indices dichotomized using values. Cox proportional hazard model for univariate (UVA) multivariate (MVA) analyses (hazard...
Personalized dosimetry holds promise to improve radioembolization treatment outcomes in hepatocellular carcinoma (HCC) patients. To this end, tolerance absorbed doses for nontumor liver tissue are assessed by calculating the mean dose whole (AD-WNTLT), which may be limited its neglect of nonuniform distribution. Thus, we analyzed whether voxel-based could more accurate predicting hepatotoxicity HCC patients undergoing radioembolization. Methods: In total, 176 were available retrospective...
Recommended treatment options for advanced-stage hepatocellular carcinoma (HCC) include systemic therapy (ST) and trans-arterial radioembolization (TARE) with Yttrium-90 (Y90). Before the approval of immune-checkpoint inhibitors, a similar safety profile was reported TARE ST tyrosine kinase inhibitors (TKI). However, whole-liver underlying cirrhosis were identified as risk factors potentially lethal radioembolization-induced liver disease (REILD). Therefore, efficacy atezolizumab/bevacizumab...
The tyrosine kinase inhibitors (TKIs) sorafenib and lenvatinib represent the first-line systemic therapy of choice for patients with hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). Under lenvatinib, HCC have shown increasingly improved overall survival in clinical studies over years. In contrast, data on LT under TKIs are scarce limited to small retrospective series. this retrospective, multicenter study, we investigated efficacy TKI influence immunosuppression LT.
The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hepatocellular carcinoma (HCC) remains unclear. Therefore, sequential systemic after first-line sorafenib or lenvatinib was compared a retrospective real-world cohort. In total, 164 HCC were included. Child B cirrhosis present 26 (16.5%), whereas 132 (83.5%) had preserved liver function. 72 (44%) discontinued while 51 (31%) and 31 (19%) received 2 more lines. Most notably, median overall survival...
Aim Evaluation of efficacy and safety atezolizumab+bevacizumab in real-world patients with impaired liver function prior systemic therapy.
Ziel/Aim Personalized dosimetry holds promise to improve radioembolization treatment outcomes in hepatocellular carcinoma (HCC) patients. To this end, tolerance doses for healthy liver tissue (HLT) are assessed by calculating the mean whole-liver normal dose (WLNT), which neglects non-uniform distribution. Thus, we analyzed whether voxel-based could be more accurate predicting hepatotoxicity HCC patients undergoing radioembolization.